Related Experiment Video
Updated: Jul 21, 2025
13:07
A Protocol for Transcranial Photobiomodulation Therapy in Mice
Published on: November 18, 2018
12.2K
Protocol Report on the Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) Study
Dan V Iosifescu1,2, Xiaotong Song2, Maia B Gersten3
1Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.
Healthcare (Basel, Switzerland)
|July 29, 2023
Summary
This study investigates transcranial photobiomodulation (t-PBM) for Alzheimer's disease (AD) and mild cognitive impairment (aMCI). Results suggest t-PBM may improve cognition and brain function in these populations.
Area of Science:
- Neuroscience
- Medical Technology
- Gerontology
Background:
- Alzheimer's disease (AD) prevalence is rising, with limited treatment options.
- Transcranial photobiomodulation (t-PBM) uses near-infrared light to potentially improve brain function.
- Preliminary findings indicate t-PBM may enhance cognition in early AD and amnestic mild cognitive impairment (aMCI).
Purpose of the Study:
- To evaluate the efficacy and safety of t-PBM in individuals with aMCI and early AD.
- To explore the mechanisms underlying t-PBM's effects on cognition and brain function.
- To assess t-PBM's potential as a low-cost, accessible therapeutic intervention.
Main Methods:
- A randomized, double-blind, placebo-controlled study involving 24 t-PBM sessions over 8 weeks.
- Investigating the moderating role of baseline tau burden and changes in mitochondrial function on cognitive outcomes.
- Utilizing fMRI BOLD signal changes after single treatment to confirm increased prefrontal cortex blood flow.
Main Results:
- This section is to be filled once the study is completed and results are available.
Conclusions:
- This study will determine if t-PBM can improve cognitive function and daily living in individuals with aMCI and early AD.
- Findings could support t-PBM as a novel, accessible treatment for neurodegenerative conditions.
